WallStreetZenWallStreetZen

NASDAQ: PTGX
Protagonist Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PTGX

Based on 6 analysts offering 12 month price targets for Protagonist Therapeutics Inc

Min Forecast
$57.00+24.4%
Avg Forecast
$69.33+51.32%
Max Forecast
$80.00+74.6%

Should I buy or sell PTGX stock?

Based on 6 analysts offering ratings for Protagonist Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 33.33%
Buy
4 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PTGX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates PTGX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their PTGX stock forecasts and price targets.

PTGX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-10
lockedlocked$00.00+00.00%2025-03-28
lockedlocked$00.00+00.00%2025-03-11
lockedlocked$00.00+00.00%2025-03-11
lockedlocked$00.00+00.00%2025-03-10
JP Morgan
Bottom 5%
5
Strong BuyMaintains$57.00+24.40%2025-03-04
Anonymous
Goldman Sachs
HoldMaintains$38.00-17.07%2025-02-24

1 of 1

Forecast return on equity

Is PTGX forecast to generate an efficient return?

Company
6.64%
Industry
142.9%
Market
80.27%
PTGX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PTGX forecast to generate an efficient return on assets?

Company
6.02%
Industry
35.65%
PTGX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PTGX earnings per share forecast

What is PTGX's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.23-127.48%
Avg 2 year Forecast
-$0.38-108.57%
Avg 3 year Forecast
-$1.24-127.74%

PTGX revenue forecast

What is PTGX's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$97.8M-77.49%
Avg 2 year Forecast
$189.6M-56.36%
Avg 3 year Forecast
$111.1M-74.42%
PTGX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PTGX revenue growth forecast

How is PTGX forecast to perform vs Biotechnology companies and vs the US market?

Company
-30.6%
Industry
64.17%
Market
10.07%
PTGX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PTGX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PTGX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PTGX$45.82$69.33+51.32%Strong Buy
IMVT$16.15$38.00+135.29%Strong Buy
XENE$38.20$58.00+51.83%Strong Buy
MLTX$42.08$75.80+80.13%Buy
CPRX$24.29$33.20+36.68%Strong Buy
View Top Biotech Stocks

Protagonist Therapeutics Stock Forecast FAQ

Is Protagonist Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: PTGX) stock is to Strong Buy PTGX stock.

Out of 6 analysts, 2 (33.33%) are recommending PTGX as a Strong Buy, 4 (66.67%) are recommending PTGX as a Buy, 0 (0%) are recommending PTGX as a Hold, 0 (0%) are recommending PTGX as a Sell, and 0 (0%) are recommending PTGX as a Strong Sell.

If you're new to stock investing, here's how to buy Protagonist Therapeutics stock.

What is PTGX's earnings growth forecast for 2025-2027?

(NASDAQ: PTGX) Protagonist Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.

Protagonist Therapeutics's earnings in 2025 is $275,188,000.On average, 6 Wall Street analysts forecast PTGX's earnings for 2025 to be -$75,398,322, with the lowest PTGX earnings forecast at -$148,549,979, and the highest PTGX earnings forecast at $34,989,045. On average, 6 Wall Street analysts forecast PTGX's earnings for 2026 to be -$23,528,598, with the lowest PTGX earnings forecast at -$159,599,151, and the highest PTGX earnings forecast at $181,083,653.

In 2027, PTGX is forecast to generate -$76,116,518 in earnings, with the lowest earnings forecast at -$127,679,321 and the highest earnings forecast at -$23,939,873.

What is PTGX's revenue growth forecast for 2025-2027?

(NASDAQ: PTGX) Protagonist Therapeutics's forecast annual revenue growth rate of -30.6% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.

Protagonist Therapeutics's revenue in 2025 is $434,433,000.On average, 5 Wall Street analysts forecast PTGX's revenue for 2025 to be $6,003,383,464, with the lowest PTGX revenue forecast at $982,148,624, and the highest PTGX revenue forecast at $13,811,465,025. On average, 5 Wall Street analysts forecast PTGX's revenue for 2026 to be $11,638,338,426, with the lowest PTGX revenue forecast at $1,227,685,780, and the highest PTGX revenue forecast at $27,546,199,689.

In 2027, PTGX is forecast to generate $6,821,942,958 in revenue, with the lowest revenue forecast at $2,885,061,583 and the highest revenue forecast at $12,114,803,277.

What is PTGX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: PTGX) forecast ROA is 6.02%, which is lower than the forecast US Biotechnology industry average of 35.65%.

What is PTGX's Price Target?

According to 6 Wall Street analysts that have issued a 1 year PTGX price target, the average PTGX price target is $69.33, with the highest PTGX stock price forecast at $80.00 and the lowest PTGX stock price forecast at $57.00.

On average, Wall Street analysts predict that Protagonist Therapeutics's share price could reach $69.33 by Apr 10, 2026. The average Protagonist Therapeutics stock price prediction forecasts a potential upside of 51.32% from the current PTGX share price of $45.82.

What is PTGX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: PTGX) Protagonist Therapeutics's current Earnings Per Share (EPS) is $4.47. On average, analysts forecast that PTGX's EPS will be -$1.23 for 2025, with the lowest EPS forecast at -$2.42, and the highest EPS forecast at $0.57. On average, analysts forecast that PTGX's EPS will be -$0.38 for 2026, with the lowest EPS forecast at -$2.60, and the highest EPS forecast at $2.95. In 2027, PTGX's EPS is forecast to hit -$1.24 (min: -$2.08, max: -$0.39).

What is PTGX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: PTGX) forecast ROE is 6.64%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.